What Researchers Did
Researchers conducted a randomized controlled trial comparing hyperbaric oxygen therapy plus pharmacological treatment to pharmacological treatment alone for transient bone marrow oedema syndrome of the hip.
What They Found
At 3 months, the hyperbaric oxygen group had a significantly higher average WOMAC score (70.8 points) compared to the control group (56.4 points, p<0.001). Magnetic Resonance Imaging also showed resolution of bone marrow oedema in 55.0% of patients receiving hyperbaric oxygen, versus 28% in the control group.
What This Means for Canadian Patients
Canadian patients experiencing transient bone marrow oedema syndrome of the hip might experience faster recovery of hip function if hyperbaric oxygen therapy is added to their pharmacological treatment. This could potentially lead to quicker pain relief and improved mobility.
Canadian Relevance
This study was not conducted in Canada and does not have direct Canadian relevance.
Study Limitations
The study's relatively small sample size and single-center design may limit the generalizability of these findings.